PMID: 9179510Apr 14, 1997Paper

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients

Drug and Alcohol Dependence
T EissenbergM L Stitzer

Abstract

Buprenorphine's clinical utility as an opioid dependence pharmacotherapy may be enhanced with less-than-daily dosing. This study assessed opioid withdrawal after an acute 72 h dose omission in buprenorphine-maintained patients (8 mg/day s.l.). Eight outpatients required to remain free of opioids, cocaine and benzodiazepines completed four double-blind, double-dummy, Latin-square ordered conditions. Test conditions of 8 or 16 mg s.l. buprenorphine were followed by 2 days of placebo dosing. Control conditions were buprenorphine maintenance (8 mg/day), to provide a reference for evaluation of placebo test days and naloxone administration (10 mg 70 kg i.m.) during 8 mg buprenorphine maintenance to assess withdrawal measure sensitivity. Subjective measures and pupil diameter were significantly influenced only by naloxone. The lack of subjective symptoms and physiological signs of opioid withdrawal during 72 h of acute dose omission supports the feasibility of less-than-daily dosing at buprenorphine doses of 8 mg/day in patients who have demonstrated an ability to remain drug-free for an extended period.

References

Aug 1, 1977·British Journal of Pharmacology·A CowanI R Macfarlane
Jun 1, 1991·The American Journal of Drug and Alcohol Abuse·T R KostenH D Kleber
Feb 8, 1980·Science·N K Mello, J H Mendelson
Apr 1, 1994·Drug and Alcohol Dependence·M I RosenT R Kosten
Oct 1, 1994·Drug and Alcohol Dependence·L J CheskinR E Johnson
Jun 1, 1993·The Journal of Nervous and Mental Disease·T R KostenJ Falcioni
Feb 1, 1997·Psychopharmacology·E C StrainG E Bigelow

❮ Previous
Next ❯

Citations

Aug 6, 2013·Paediatric Drugs·Anna PecoraroGeorge E Woody
Jun 23, 2000·Biological Psychiatry·R S SchottenfeldT R Kosten
Jan 8, 1999·Peptides·G A OlsonA J Kastin
May 10, 2003·Drug and Alcohol Dependence·Sharon L Walsh, Thomas Eissenberg
May 10, 2003·Drug and Alcohol Dependence·Rolley E JohnsonLeslie Amass
Jul 13, 1999·Drug and Alcohol Dependence·M C ChawarskiJ Pakes
Feb 14, 2007·Experimental and Clinical Psychopharmacology·Stacey C Sigmon
May 27, 2003·British Journal of Anaesthesia·K Budd, B J Collett
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Jason M White, Olga V Lopatko
Apr 14, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment, Guidelines for Substance Use Disorders
Jun 9, 2012·Substance Use & Misuse·Anna PecoraroGeorge E Woody
Oct 22, 2008·Drug and Alcohol Dependence·Stephen MaguraAndrew Rosenblum
Oct 1, 2004·Acta Neuropsychiatrica·Fergus D LawDavid J Nutt
Dec 12, 2018·Journal of Addiction Medicine·Marion A CoeSharon L Walsh
Dec 26, 2001·The Journal of Pharmacology and Experimental Therapeutics·Tatiana NanovskayaMahmoud S Ahmed
Dec 20, 2007·British Journal of Hospital Medicine·Sanju George, Ed Day

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.